Iran Memorial

Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial

Reuters2/23/2026

Summary

No summary yet.

Share:XRedditLinkedIn

Advertisement

Lindy Score Breakdown (V4.2)

7h
Age
2
Sources
from cluster
6
Hours Since Seen
Final Score25/100
CategoryBreaking
StatusActive
Recency Multiplier92% (0.5^6/48)
Hero EligibleYes

Story Timeline

  1. 2026-02-23
    Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial (current)

Score BreakdownRisk 40

Source Reputation: Moderate trust (10/20 pts)
Consensus: Emerging consensus: 2 sources
Age: Breaking news - too recent to assess longevity

Stories gain Lindy status through source reputation, network consensus, and time survival.

Same Story from 2 sources

Breaking Similar stories

Anti-Lindy Similar stories